Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotechnology Surging
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech plunges on drug side effects
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales - Yahoo Sports
Articles about Puma Biotechnology
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotech granted Orphan Drug status for lung cancer candida | Seeking Alpha
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotech Rebranding — Alex Maurer Designs
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech Is up 181% This Year; Here's Why It Can Still Go Higher - Barron's
Biotech Entrepreneur's Fortune Nearly Doubles After Strong Clinical Trials For Cancer Treatment
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High | Investor's Business Daily
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock
